默沙东 - 五年后,Keytruda联合Lenvima在患有缺失修复正常(Pmmr)晚期子宫内膜癌患者中展现了16.7%的生存率

美股速递
Oct 18, 2025

默沙东 - 五年后,Keytruda联合Lenvima在患有缺失修复正常(Pmmr)晚期子宫内膜癌患者中展现了16.7%的生存率

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10